optimal_bias            Optimal phase II/III drug development planning
                        for time-to-event endpoints when discounting
                        phase II results
optimal_bias_binary     Optimal phase II/III drug development planning
                        when discounting phase II results with binary
                        endpoint
optimal_bias_normal     Optimal phase II/III drug development planning
                        when discounting phase II results with normally
                        distributed endpoint
optimal_binary          Optimal phase II/III drug development planning
                        with binary endpoint
optimal_multiarm        Optimal phase II/III drug development planning
                        for multi-arm programs with time-to-event
                        endpoint
optimal_multiarm_binary
                        Optimal phase II/III drug development planning
                        for multi-arm programs with binary endpoint
optimal_multiarm_normal
                        Optimal phase II/III drug development planning
                        for multi-arm programs with normally
                        distributed endpoint
optimal_multiple_normal
                        Optimal phase II/III drug development planning
                        for programs with multiple normally distributed
                        endpoints
optimal_multiple_tte    Optimal phase II/III drug development planning
                        for programs with multiple time-to-event
                        endpoints
optimal_multitrial      Optimal phase II/III drug development planning
                        where several phase III trials are performed
                        for time-to-event endpoints
optimal_multitrial_binary
                        Optimal phase II/III drug development planning
                        where several phase III trials are performed
optimal_multitrial_normal
                        Optimal phase II/III drug development planning
                        where several phase III trials are performed
optimal_normal          Optimal phase II/III drug development planning
                        with normally distributed endpoint
optimal_tte             Optimal phase II/III drug development planning
                        with time-to-event endpoint
